Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Hochhaus, A ^a,c   Dreyling, M ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; CANCER INCIDENCE; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MOLECULAR GENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE;

FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM STAGING;

EID: 45149091617     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn091     Document Type: Article

References (10)

1. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
2. Bonifazi F, De Vivo A, Rosti G et al. Chronic myeloid leukemia and interferonalpha: A study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
3. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
4. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692.
5. Hughes TP, Deininger MW, Hochhaus A et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
6. Kantarjian H, Giles F, Wunderle L et al. Nilotinib (AMN107), a novel, highly active, selective BCR-ABL tyrosine kinase inhibitor in patients with Philadelphiachromosome (Ph) positive chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) who are resistant to imatinib mesylate therapy. N Engl J Med 2006; 354: 2542-2551.
7. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
8. Ries LAG, Melbert D, Krapcho M et al. SEER cancer statistics review, 1975-2004, National Cancer Institute. Bethesda, MD. Posted to the SEER website, 2007.
9. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good risk' chronic granulocytic leukaemia. Blood 1984; 63: 789-799.
10. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.